A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Mar 26, 2019

Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society’s Annual Meeting (ENDO) - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -

TOKYO, March 26, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from a Phase 2b dose-finding study of fezolinetant,...

Read more about Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society’s Annual Meeting (ENDO) - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -
Mar 22, 2019

Notice of Completion of Acquisition of Own Shares

Read more about Notice of Completion of Acquisition of Own Shares
Mar 4, 2019

EVENITY® SUBCUTANEOUS INJECTION 105 mg SYRINGE LAUNCHED IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS WITH HIGH RISK OF FRACTURE

TOKYO (March 4, 2019) - Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”), Astellas Pharma Inc. (Headquarters, Tokyo;...

Read more about EVENITY® SUBCUTANEOUS INJECTION 105 mg SYRINGE LAUNCHED IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS WITH HIGH RISK OF FRACTURE
Mar 1, 2019

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Feb 28, 2019

Astellas Announces Acceptance of XOSPATATM (gilteritinib) for Regulatory Review by the European Medicines Agency

TOKYO, February 28, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the submission for a marketing authorisation...

Read more about Astellas Announces Acceptance of XOSPATATM (gilteritinib) for Regulatory Review by the European Medicines Agency
Feb 11, 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Data to be presented at the 2019 Genitourinary Cancers Symposium

NEW YORK and TOKYO, Feb. 11, 2019 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase...

Read more about Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Feb 5, 2019

Astellas Announces Personnel Changes

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Jan 31, 2019

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Jan 22, 2019

Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products

Tokyo and Kumamoto, January 22, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and KM Biologics Co., Ltd. (President and Representative...

Read more about Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products
Jan 17, 2019

Transfer of Sale and Distribution, and Termination of Co-promotion for Symbicort® Turbuhaler®

TOKYO and OSAKA January 17, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and AstraZeneca K.K. (Representative Director and President: Stefan...

Read more about Transfer of Sale and Distribution, and Termination of Co-promotion for Symbicort® Turbuhaler®
Jan 9, 2019

EVENITY® SUBCUTANEOUS INJECTION 105mg SYRINGE RECEIVES THE-FIRST-IN-THE-WORLD APPROVAL IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS AT HIGH RISK OF FRACTURE

EVENITY® (romosozumab) Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Postmenopausal Women and Men With Osteoporosis

TOKYO (January 9, 2019) - Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”), Astellas Pharma Inc. (Headquarters, Tokyo;...

Read more about EVENITY® SUBCUTANEOUS INJECTION 105mg SYRINGE RECEIVES THE-FIRST-IN-THE-WORLD APPROVAL IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS AT HIGH RISK OF FRACTURE
Jan 8, 2019

Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax® for partial changes (addition of dosage and administration) and addition of Gonax® 240 mg

TOKYO, January 8, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that gonadotrophin-releasing hormone (GnRH) receptor antagonist,...

Read more about Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax® for partial changes (addition of dosage and administration) and addition of Gonax® 240 mg
Jan 8, 2019

Additional Approvals for Bisono® Tape, a Transdermal Patch containing a β1 Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan

Tokyo: January 8, 2019 - Toa Eiyo Ltd. (President: Atsuo Takahashi, Ph.D., “Toa Eiyo”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) announced today that Toa...

Read more about Additional Approvals for Bisono® Tape, a Transdermal Patch containing a β1 Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan
Dec 21, 2018

Approval of Suglat® Tablets, Selective SGLT2 Inhibitor, for Additional Indication of type 1 diabetes mellitus and Additional dosage and administration in Japan

Tokyo, December 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Kotobuki Pharmaceutical Co., Ltd. (President and CEO; Hiroshi Tomiyama,...

Read more about Approval of Suglat® Tablets, Selective SGLT2 Inhibitor, for Additional Indication of type 1 diabetes mellitus and Additional dosage and administration in Japan
Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK, Dec. 20, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES...

Read more about Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Dec 14, 2018

Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -

TOKYO, December 14, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it exercised, and closed on its exclusive option to...

Read more about Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -
Dec 11, 2018

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

TOKYO – December 11, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced that XOSPATA® (generic name: gilteritinib) is now...

Read more about Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Dec 3, 2018

Launch of XOSPATA® Tablets 40 mg in Japan - Provides a new therapeutic option for patients with AML -

TOKYO, December 3, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced the launch of the FLT3 (FMS-like tyrosine kinase 3) inhibitor...

Read more about Launch of XOSPATA® Tablets 40 mg in Japan - Provides a new therapeutic option for patients with AML -
Dec 3, 2018

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

TOKYO – December 3, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced updated results from a Phase 1 study of gilteritinib in...

Read more about Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Nov 29, 2018

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

- FLT3 mutation-positive AML is a life-threatening disease with significant unmet medical needs -

TOKYO – November 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) approved...

Read more about XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Nov 28, 2018

Cimzia® (certolizumab pegol) 200mg AutoClicks® for S.C. Injection Newly Launched

UCB Japan (headquarters: Shinjuku-ku, Tokyo; president: Kanako Kikuchi; hereafter referred to as “UCB Japan”; when referring to the global UCB group, “UCB”) and Astellas Pharma Inc....

Read more about Cimzia® (certolizumab pegol) 200mg AutoClicks® for S.C. Injection Newly Launched
Nov 27, 2018

BLINCYTO® for drip infusion 35 μg launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more about BLINCYTO® for drip infusion 35 μg launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
Nov 22, 2018

Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas

TOKYO and CLEVELAND, Ohio, November 22, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Juventas Therapeutics (President & CEO: Rahul Aras,...

Read more about Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas
Nov 20, 2018

Astellas Global Health Foundation Launches - Foundation to Support Improving Access to Health for Underserved Populations -

TOKYO and NORTHBROOK, Ill., November 20, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced the launch of the Astellas Global Health...

Read more about Astellas Global Health Foundation Launches - Foundation to Support Improving Access to Health for Underserved Populations -
Nov 19, 2018

Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -

TOKYO – November 19, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced it will present new data in Acute Myeloid Leukemia (AML)...

Read more about Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts